179324-69-7

Bortezomib (LDP 341) is a 20S proteasome inhibitor (Ki=0.6 nM) that is reversible and selective. Bortezomib has antitumor activity and inhibits NF-κB, which can disrupt the cell cycle and induce apoptosis.

(1S,2S)-Bortezomib (Bortezomib) is an enantiomer of Bortezomib. Bortezomib is a reversible and selective inhibitor of the proteasome with a Ki of 0.6 nM for 20S proteasome.

Bortezomib-D8 is the deuterated form of Bortezomib. Bortezomib (T2399) (PS-341) is a reversible and selective proteasome inhibitor that effectively targets threonine residues, inhibiting the 20S proteasome (Ki=0.6 nM). It disrupts the cell cycle, induces apoptosis, and inhibits the nuclear factor NF-κB. Bortezomib (T2399) is noted as the first proteasome inhibitor with anticancer activity.

Bortezomib-[D8] (Standard) is a reference standard of Bortezomib-[D8] intended for quantitative analysis, quality control, and related biochemical research applications.